

# Alex Hofer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5188457/publications.pdf>

Version: 2024-02-01

113  
papers

3,802  
citations

101543

36  
h-index

144013

57  
g-index

127  
all docs

127  
docs citations

127  
times ranked

4424  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurometabolite correlates with personality and stress in healthy emerging adults: A focus on sex differences. <i>NeuroImage</i> , 2022, 247, 118847.	4.2	3
2	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	2.6	13
3	Mental health in individuals with severe mental disorders during the covid-19 pandemic: a longitudinal investigation. <i>NPJ Schizophrenia</i> , 2022, 8, 17.	3.6	10
4	The Anti-social Brain in Schizophrenia: A Role of CaMKII?. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	2
5	Social interaction reward in rats has anti-stress effects. <i>Addiction Biology</i> , 2021, 26, e12878.	2.6	21
6	Sex matters: stress perception and the relevance of resilience and perceived social support in emerging adults. <i>Archives of Women's Mental Health</i> , 2021, 24, 403-411.	2.6	30
7	The relationship between emotional intelligence and quality of life in schizophrenia and bipolar I disorder. <i>Quality of Life Research</i> , 2021, 30, 2475-2485.	3.1	2
8	Resilience Predicts Self-Stigma and Stigma Resistance in Stabilized Patients With Bipolar I Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 678807.	2.6	9
9	Psychological Distress, Loneliness, and Boredom Among the General Population of Tyrol, Austria During the COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2021, 12, 691896.	2.6	19
10	Is It Possible to Shift from Down to Top Rank? A Focus on the Mesolimbic Dopaminergic System and Cocaine Abuse. <i>Biomedicines</i> , 2021, 9, 877.	3.2	4
11	Involvement of cAMP-Dependent Protein Kinase in the Nucleus Accumbens in Cocaine Versus Social Interaction Reward. <i>International Journal of Molecular Sciences</i> , 2021, 22, 345.	4.1	7
12	The Mediating Role of Resilience and Extraversion on Psychological Distress and Loneliness Among the General Population of Tyrol, Austria Between the First and the Second Wave of the COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2021, 12, 766261.	2.6	18
13	Rewarding Social Interaction in Rats Increases CaMKII in the Nucleus Accumbens. <i>Biomedicines</i> , 2021, 9, 1886.	3.2	8
14	Premorbid Social Functioning and Affective Symptoms Predict Subjective Outcome Among Outpatients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 570857.	2.6	4
15	Associations between resilience and quality of life in patients experiencing a depressive episode. <i>Psychiatry Research</i> , 2020, 292, 113353.	3.3	16
16	Emotional intelligence in bipolar-I-disorder: A comparison between patients, unaffected siblings, and control subjects. <i>European Psychiatry</i> , 2020, 63, e69.	0.2	9
17	On the difficulties of building therapeutic relationships when wearing face masks. <i>Journal of Psychosomatic Research</i> , 2020, 138, 110226.	2.6	9
18	Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer's Dementia: A Clinical Case Report. <i>Frontiers in Psychiatry</i> , 2020, 11, 413.	2.6	6

#	ARTICLE	IF	CITATIONS
19	Social interaction reward: A resilience approach to overcome vulnerability to drugs of abuse. <i>European Neuropsychopharmacology</i> , 2020, 37, 12-28.	0.7	25
20	Is p38 MAPK Associated to Drugs of Abuse-Induced Abnormal Behaviors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4833.	4.1	19
21	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.7	60
22	Combined Processing of Facial and Vocal Emotion in Remitted Patients With Bipolar I Disorder. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 275-284.	1.8	2
23	Antipsychotic-induced tardive dyskinesia. <i>Current Opinion in Psychiatry</i> , 2019, 32, 179-184.	6.3	21
24	Self-stigma versus stigma resistance in schizophrenia: Associations with resilience, premorbid adjustment, and clinical symptoms. <i>Psychiatry Research</i> , 2019, 271, 396-401.	3.3	27
25	Trends in pharmacological emergency treatment of patients suffering from schizophrenia over a 16-year observation period. <i>International Clinical Psychopharmacology</i> , 2018, 33, 197-203.	1.7	2
26	Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international cross-sectional study. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 316-327.	4.5	27
27	Characteristics of Involuntarily Admitted Patients and Treatment Patterns Over a 21-Year Observation Period. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 376-379.	1.4	0
28	Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. <i>Journal of Affective Disorders</i> , 2018, 238, 399-404.	4.1	31
29	Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. <i>BMC Psychiatry</i> , 2018, 18, 212.	2.6	11
30	Is Emotional Intelligence Impaired in Unaffected Siblings of Patients with Schizophrenia?. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 577-583.	1.8	2
31	Emotional intelligence and non-social cognition in schizophrenia and bipolar I disorder. <i>Psychological Medicine</i> , 2017, 47, 35-42.	4.5	20
32	Why do individuals with schizophrenia drop out of observational clinical trials?. <i>Psychiatry Research</i> , 2017, 256, 1-5.	3.3	9
33	Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. <i>European Psychiatry</i> , 2017, 46, 42-47.	0.2	47
34	Ability-based emotional intelligence in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2017, 30, 197-200.	6.3	2
35	Emotional Intelligence and cognitive abilities " associations and sex differences. <i>Psychology, Health and Medicine</i> , 2017, 22, 1001-1010.	2.4	27
36	Therapeutic Alliance in Patients With Schizophrenia: Introduction of a New Rating Instrument. <i>Journal of Psychiatric Practice</i> , 2016, 22, 298-307.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Emotional Intelligence deficits in schizophrenia: The impact of non-social cognition. <i>Schizophrenia Research</i> , 2016, 172, 131-136.	2.0	21
38	Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: A cross-sectional study. <i>Schizophrenia Research</i> , 2016, 175, 148-153.	2.0	50
39	Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self-esteem. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 360-367.	4.5	56
40	Prescribing Practice in Inpatients Versus Outpatients With Schizophrenia Initiating Treatment With Second-Generation Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 621-627.	1.4	4
41	Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: Cultural comparison in Austria and Japan. <i>Schizophrenia Research</i> , 2016, 171, 86-91.	2.0	63
42	Emotional Intelligence and resilience in mental health professionals caring for patients with serious mental illness. <i>Psychology, Health and Medicine</i> , 2016, 21, 755-761.	2.4	13
43	Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting. <i>European Neuropsychopharmacology</i> , 2016, 26, 717-728.	0.7	6
44	Bilirubin Concentration Correlates With Positive Symptoms in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 512-516.	2.2	10
45	Psychiatric misdiagnoses in Dandy-Walker variant. <i>Neurocase</i> , 2015, 21, 499-500.	0.6	7
46	Measuring Adherence to Medication in Schizophrenia: The Relationship between Attitudes toward Drug Therapy and Plasma Levels of New-Generation Antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu091-pyu091.	2.1	9
47	Neurology Issues in Schizophrenia. <i>Current Psychiatry Reports</i> , 2015, 17, 32.	4.5	16
48	Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 474-475.	1.4	5
49	Prosodic and Semantic Affect Perception in Remitted Patients With Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e779-e786.	2.2	8
50	Sibutramine in the treatment of antipsychotic-induced weight gain. <i>International Clinical Psychopharmacology</i> , 2014, 29, 181-184.	1.7	15
51	Facial affect recognition in symptomatically remitted patients with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2014, 152, 440-445.	2.0	42
52	Risk of violence of inpatients with severe mental illness – Do patients with schizophrenia pose harm to others?. <i>Psychiatry Research</i> , 2014, 219, 450-456.	3.3	13
53	Social cognition in serious mental illness. <i>Current Opinion in Psychiatry</i> , 2014, 27, 197-202.	6.3	65
54	Affective prosody perception in symptomatically remitted patients with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2014, 158, 100-104.	2.0	19

#	ARTICLE	IF	CITATIONS
55	Pulmonary Embolism and Aspiration Pneumonia After Reexposure to Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 385-387.	1.4	14
56	Pharmacological Strategies to Enhance Adherence in Schizophrenia. , 2014, , 85-97.		2
57	Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. <i>International Clinical Psychopharmacology</i> , 2013, 28, 1.	1.7	12
58	Theory of mind and its relevance in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2012, 25, 71-75.	6.3	56
59	Aripiprazole Use in Early Pregnancy: A Case Report. <i>Pharmacopsychiatry</i> , 2012, 45, 299-300.	3.3	14
60	Management of a Risperidone-Induced Tardive Pisa Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 418-420.	1.4	8
61	Schizophrenie, schizotype und wahnhafte Störungen (ICD-10 F2). , 2012, , 111-151.		1
62	Combined Clozapine and Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia. <i>Journal of ECT</i> , 2011, 27, e61-e62.	0.6	12
63	Facial emotion recognition and its relationship to subjective and functional outcomes in remitted patients with bipolar I disorder. <i>Bipolar Disorders</i> , 2011, 13, 537-544.	1.9	70
64	Symptomatic remission and neurocognitive functioning in patients with schizophrenia. <i>Psychological Medicine</i> , 2011, 41, 2131-2139.	4.5	42
65	Prolactin Levels and Sexual Adverse Effects in Patients With Schizophrenia During Antipsychotic Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 711-715.	1.4	38
66	Pharmacological Interventions. <i>Key Issues in Mental Health</i> , 2010, , 145-157.	0.6	1
67	Aripiprazole Add-On Treatment in a Patient with Schizoaffective Disorder: Neurocognitive Outcomes. <i>Pharmacopsychiatry</i> , 2010, 43, 234-235.	3.3	1
68	Neutropenia Induced by Second Generation Antipsychotics: A Prospective Investigation. <i>Pharmacopsychiatry</i> , 2010, 43, 41-44.	3.3	37
69	Attitudes of patients with schizophrenia and depression towards psychiatric research. <i>Psychiatry Research</i> , 2010, 177, 172-176.	3.3	10
70	Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. <i>Schizophrenia Research</i> , 2009, 113, 246-251.	2.0	24
71	Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia. <i>European Psychiatry</i> , 2009, 24, 27-32.	0.2	81
72	Schizophrenie Störungen. , 2008, , 847-872.		1

#	ARTICLE	IF	CITATIONS
73	Outcomes in Schizophrenia Outpatients Treated with Amisulpride or Olanzapine. <i>Pharmacopsychiatry</i> , 2007, 40, 1-8.	3.3	19
74	Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. <i>Journal of Psychopharmacology</i> , 2007, 21, 400-404.	4.0	13
75	Sex differences in brain activation patterns during processing of positively and negatively valenced emotional words. <i>Psychological Medicine</i> , 2007, 37, 109-119.	4.5	84
76	Quetiapine Cross Reactivity With Urine Methadone Immunoassays. <i>American Journal of Psychiatry</i> , 2007, 164, 172-172.	7.2	29
77	The neural regions sustaining episodic encoding and recognition of objects. <i>Brain and Cognition</i> , 2007, 63, 159-166.	1.8	17
78	Neural substrates for episodic encoding and recognition of unfamiliar faces. <i>Brain and Cognition</i> , 2007, 63, 174-181.	1.8	31
79	Cognitive impairment in schizophrenia: Clinical ratings are not a suitable alternative to neuropsychological testing. <i>Schizophrenia Research</i> , 2007, 92, 126-131.	2.0	27
80	Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 354-361.	4.5	36
81	Brain activation patterns during a selective attention test – a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2007, 154, 31-40.	1.8	69
82	Gender differences in regional cerebral activity during the perception of emotion: A functional MRI study. <i>NeuroImage</i> , 2006, 32, 854-862.	4.2	143
83	Language lateralization in unmedicated patients during an acute episode of schizophrenia: A functional MRI study. <i>Psychiatry Research - Neuroimaging</i> , 2006, 146, 185-190.	1.8	82
84	Association Between Antipsychotic-induced Elevation of Liver Enzymes and Weight Gain. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 500-503.	1.4	16
85	Early changes of plasma lipids during treatment with atypical antipsychotics. <i>International Clinical Psychopharmacology</i> , 2006, 21, 369-372.	1.7	31
86	Attitudes towards medication in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 161-162.	4.5	21
87	Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 246-255.	3.2	77
88	Evoluci3n de los pacientes en la esquizofrenia I: correlatos con variables sociodemogrÃ¡ficas, manifestaciones psicopatolÃ³gicas y efectos secundarios. <i>European Psychiatry (Ed EspaÃ±ola)</i> , 2006, 13, 77-85.	0.0	0
89	Evoluci3n de los pacientes en la esquizofrenia II: el impacto de la cognici3n. <i>European Psychiatry (Ed Tj ETQq1</i>	1.0	0
90	QTc Variability in Schizophrenia Patients Treated With Antipsychotics and Healthy Controls. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 206-210.	1.4	17

#	ARTICLE	IF	CITATIONS
91	Erratum. Journal of Clinical Psychopharmacology, 2005, 25, 201.	1.4	11
92	Osteoporosis in Patients With Schizophrenia. American Journal of Psychiatry, 2005, 162, 162-167.	7.2	114
93	Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. European Psychiatry, 2005, 20, 386-394.	0.2	59
94	Patient outcomes in schizophrenia II: the impact of cognition. European Psychiatry, 2005, 20, 395-402.	0.2	119
95	The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophrenia Research, 2005, 75, 143-146.	2.0	20
96	Brain activation patterns during a verbal fluency test? a functional MRI study in healthy volunteers and patients with schizophrenia. Schizophrenia Research, 2004, 70, 287-291.	2.0	91
97	Psychopharmakotherapie in der Rehabilitation. , 2004, , 129-133.		4
98	Quality of Life in Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 932-939.	2.2	132
99	Reply to Psychotic Symptoms Associated With Topiramate: Cognitive Side Effects or Worsening of Psychosis?. Journal of Clinical Psychiatry, 2004, 65, 1145-1146.	2.2	4
100	Compliance in Schizophrenia: Psychopathology, Side Effects, and Patients' Attitudes Toward the Illness and Medication. Journal of Clinical Psychiatry, 2004, 65, 1211-1218.	2.2	104
101	Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. Journal of Clinical Psychiatry, 2004, 65, 932-9.	2.2	44
102	Brain activation patterns during a selective attention test? a functional MRI study in healthy volunteers and patients with schizophrenia. Psychiatry Research - Neuroimaging, 2003, 123, 1-15.	1.8	64
103	Brain activation pattern during a verbal fluency test in healthy male and female volunteers: a functional magnetic resonance imaging study. Neuroscience Letters, 2003, 352, 191-194.	2.1	104
104	Sex differences in brain activation pattern during a visuospatial cognitive task: a functional magnetic resonance imaging study in healthy volunteers. Neuroscience Letters, 2003, 344, 169-172.	2.1	236
105	The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology, 2003, 6, 201-206.	2.1	16
106	Neural Correlates of Episodic Encoding and Recognition of Words in Unmedicated Patients During an Acute Episode of Schizophrenia: A Functional MRI Study. American Journal of Psychiatry, 2003, 160, 1802-1808.	7.2	39
107	An fMRI Study of Episodic Encoding and Recognition of Words in Patients With Schizophrenia in Remission. American Journal of Psychiatry, 2003, 160, 911-918.	7.2	65
108	Attitudes of Patients With Schizophrenia Toward Placebo-Controlled Clinical Trials. Journal of Clinical Psychiatry, 2003, 64, 277-281.	2.2	50

#	ARTICLE	IF	CITATIONS
109	Olanzapine Induces Insulin Resistance. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1436-1439.	2.2	72
110	Advances in the neuroimaging of cognitive functions in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2002, 15, 3-7.	6.3	5
111	Attitudes Toward Antipsychotics Among Outpatient Clinic Attendees With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 49-53.	2.2	77
112	Association of Olanzapine-Induced Weight Gain With an Increase in Body Fat. <i>American Journal of Psychiatry</i> , 2001, 158, 1719-1722.	7.2	151
113	Selection Bias in Clinical Trials With Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 699-702.	1.4	94